Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Drug

Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials

Fineline Cube Jul 18, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical...

Company Drug

Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004

Fineline Cube Jul 18, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao...

Company Drug

Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales

Fineline Cube Jul 18, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) reported that sales of Carvykti reached USD 439 million...

Company Deals

Buchang Pharma Subsidiary Establishes Shaanxi Buchang MedData with Lingyishushu

Fineline Cube Jul 18, 2025

Shandong Buchang Chuanfang, a subsidiary of China-based Buchang Pharma (SHA: 603858), announced the establishment of...

Company

Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands

Fineline Cube Jul 17, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) reported double-digit growth in both revenue and net income...

Company Drug

Takeda’s Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials

Fineline Cube Jul 17, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that both Phase 3 randomized, double-blind, placebo-controlled...

Company Deals

PHASE Scientific Partners with Lumos Diagnostics to Launch FebriDx in US Respiratory Market

Fineline Cube Jul 17, 2025

China-based PHASE Scientific has entered into an exclusive distribution agreement with Lumos Diagnostics to introduce...

Company Drug

Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China

Fineline Cube Jul 17, 2025

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have submitted a supplemental new-drug application...

Company

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance

Fineline Cube Jul 17, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced its second-quarter 2025 (2025Q2) results, reporting...

Company Policy / Regulatory

Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development

Fineline Cube Jul 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China’s Center for Drug...

Company Drug

Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders

Fineline Cube Jul 17, 2025

Hainan Boao Research Hospital, operated by Shanghai’s Ruijin Hospital, has obtained provincial approval to import...

Company Drug

Sanofi’s Gene Therapy SAR446597 Secures FDA Fast Track for Geographic Atrophy

Fineline Cube Jul 17, 2025

France-based Sanofi (NASDAQ: SNY) announced that its one-time intravitreal gene therapy SAR446597 has received FDA...

Company Deals

Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development

Fineline Cube Jul 16, 2025

China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40...

Company Drug

Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment

Fineline Cube Jul 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....

Company Drug

Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388

Fineline Cube Jul 16, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Deals

Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System

Fineline Cube Jul 16, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between...

Company Drug

AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial

Fineline Cube Jul 16, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...

Company Medical Device

Shanghai Sanyou Medical Receives NMPA Marketing License for JAZZ Spinal Fixation System

Fineline Cube Jul 16, 2025

Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced that it has received the marketing license...

Policy / Regulatory

NMPA Updates Reference Drugs for GQCE Evaluation: 42 New Additions and 6 Removals

Fineline Cube Jul 16, 2025

China’s National Medical Products Administration (NMPA) has released the 94th batch of reference drugs for...

Company Deals

BD Merges Biosciences & Diagnostic Solutions with Waters Corporation in USD 17.5 Billion Deal

Fineline Cube Jul 16, 2025

US major Becton, Dickinson and Co., (BD) is set to merge its Biosciences & Diagnostic...

Posts pagination

1 … 127 128 129 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.